SLU-P322 5mg

SLU-PP-332 is a potent synthetic small-molecule agonist of the estrogen-related receptors (ERRs), with high affinity for ERRα (EC₅₀ = 98 nM). Widely characterized in preliminary research as an "exercise mimetic," it works by activating metabolic pathways that mirror the physiological effects of physical exercise — including enhanced mitochondrial function, increased fatty acid oxidation, and improved skeletal muscle performance — without requiring physical exertion. Research interest has expanded to include obesity, metabolic syndrome, fatty liver disease, heart failure, and kidney disease.

Note: This compound is sometimes listed as SLU-PP-322 or SLU-P322; SLU-PP-332 is the correct scientific designation.

Chemical Makeup Molecular Weight: 383.4 g/mol | CAS No: 2172451-05-5 | Target: ERRα / ERRβ / ERRγ agonist

Research Highlights

• Exercise Mimetic — Studies in animal models suggest SLU-PP-332 may stimulate metabolic pathways associated with endurance exercise, potentially increasing metabolic rate and energy expenditure without physical activity.
• Fat Reduction & Metabolic Function — Research in murine models of metabolic syndrome indicates the compound may reduce fat mass and improve insulin sensitivity, with observed reductions in markers associated with obesity and glucose dysregulation.
• Muscle Performance — Animal studies found SLU-PP-332 may increase the proportion of oxidative muscle fibers in skeletal muscle and improve exercise endurance, suggesting potential applications in muscle function and fatigue research.
• Fatty Liver Disease — Preliminary research points to SLU-PP-332's potential in reducing hepatic fat accumulation and improving liver function markers in non-alcoholic fatty liver disease models.
• Cardiac & Renal Research — Researchers are actively investigating the compound's potential in heart failure and kidney disease models, given its role in mitochondrial energy pathway activation across multiple tissue types.
• COVID-19 — Early research has explored whether SLU-PP-332 may reduce viral entry points in adipose tissue, with some studies suggesting a potential role in limiting COVID-19 susceptibility in metabolically compromised models.

Available for research and laboratory purposes only.